"The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug receiv"...
Chemotherapy-Induced Nausea And Vomiting In Adults
ALOXI is indicated for:
- Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
- Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses
Chemotherapy-Induced Nausea And Vomiting In Pediatric Patients Aged 1 Month To Less than 17 Years
ALOXI is indicated for prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.
Postoperative Nausea And Vomiting In Adults
ALOXI is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.
As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, ALOXI is recommended even where the incidence of postoperative nausea and/or vomiting is low.
DOSAGE AND ADMINISTRATION
Chemotherapy-Induced Nausea and Vomiting
|Adults||0.25 mg x 1||Infuse over 30 seconds beginning approx. 30 min before the start of chemo|
|Pediatrics (1 month to less than 17 years)||20 micrograms per kilogram (max 1.5 mg) x 1||Infuse over 15 minutes beginning approx. 30 min before the start of chemo|
|*Note different dosing units in pediatrics|
Postoperative Nausea And Vomiting
Dosage for Adults - a single 0.075 mg intravenous dose administered over 10 seconds immediately before the induction of anesthesia.
Instructions For Intravenous Administration
ALOXI is supplied ready for intravenous administration at a concentration of 0.05 mg/mL (50 mcg/ mL). ALOXI should not be mixed with other drugs. The infusion line should be flushed with normal saline before and after administration of ALOXI. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever solution and container permit.
Dosage Form And Strengths
ALOXI is supplied as a single-use sterile, clear, colorless solution in glass vials that provide:
- 0.25 mg (free base) per 5 mL (concentration: 0.05 mg/mL, 50 mcg/mL)
- 0.075 mg (free base) per 1.5 mL (concentration: 0.05 mg/mL, 50 mcg/mL)
Storage And Handling
NDC #62856-797-01, ALOXI Injection 0.25 mg/5 mL (free base)single-use vial individually packaged in a carton.
NDC #62856-798-01, ALOXI Injection 0.075 mg/1.5 mL (free base)single-use vial packaged in a carton containing5 vials.
- Store at controlled temperature of 20–25°C (68°F–77°F).Excursions permitted to 15–30°C (59-86°F).
- Protect from freezing.
- Protect from light.
Mfd by OSO Biopharmaceuticals, LLC, Albuquerque, NM, USA or Pierre Fabre, Médicament Production, Idron, Aquitaine, France and Helsinn Birex Pharmaceuticals, Dublin, Ireland. Revised: Sep 2014This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/14/2016
Additional Aloxi Information
Aloxi - User Reviews
Aloxi User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.